Deciphera Pharmaceuticals Stock

Deciphera Pharmaceuticals EPS

Delisted·Jun 10, 2024

The Earnings per Share (EPS) of Deciphera Pharmaceuticals (DCPH) as of Aug 4, 2026 is -2.29 USD. In the previous year, Earnings per Share (EPS) was -2.35 USD — a change of -2.59% (higher).

EPS

-2.29USD

YoY

-2.59%

Last updated:

Earnings per Share (EPS) of Deciphera Pharmaceuticals is 2026 -2.29 USD. Earnings per Share (EPS) of Deciphera Pharmaceuticals was 2025 -2.35 USD. It decreases by -2.59% higher compared to the previous year.
Access this data via the Eulerpool API

Deciphera Pharmaceuticals Stock analysis

What does Deciphera Pharmaceuticals do? Deciphera Pharmaceuticals Inc is a US biopharmaceutical company specializing in the research, development, and marketing of innovative therapeutic solutions for cancer patients. The company was founded in 2003 and is headquartered in Waltham, Massachusetts. Deciphera follows a diversified business model based on multiple pillars. On one hand, the company conducts its own research and development activities to develop new therapy approaches for cancer patients. Deciphera focuses on the research of kinase inhibitors, which offer promising approaches in cancer therapy. On the other hand, the company pursues a licensing strategy by acquiring and further developing already developed active ingredients for cancer therapies in order to make them available to patients. For this purpose, the company collaborates with various partner companies and leading academics and experts in the field of cancer therapy. Deciphera is also engaged in international collaboration through partnerships with local partners in Asia for the research of new cancer therapy approaches. The company invests significant efforts in research and development to constantly adapt its products to the latest scientific advances. Deciphera aims to develop effective and safe therapies for cancer patients that improve their quality of life and increase their chances of survival. The company relies on the research of kinase inhibitors that specifically target certain signaling pathways in cancer cells and thereby inhibit the growth of tumor cells. The company already has a number of products in clinical trials and approval processes that show promising results and are expected to be on the market soon. One promising drug is Ripretinib, dedicated to the cancer type GIST. The goal is to offer a range of cancer medications that have significant treatment success and offer customers high chances of success. Overall, Deciphera Pharmaceuticals is a dynamic and research-oriented company that utilizes the most innovative technologies to give hope to cancer patients and improve the treatment of cancer diseases. With its broad portfolio of active ingredients and therapy approaches, its international presence, and its dedicated research and development, Deciphera Pharmaceuticals Inc. is at the forefront when it comes to innovative cancer treatment therapies. Deciphera Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Deciphera Pharmaceuticals stock

Earnings per Share (EPS) of Deciphera Pharmaceuticals is -2.29 USD in 2026.

Earnings per Share (EPS) of Deciphera Pharmaceuticals changed from -2.35 USD to -2.29 USD, representing a -2.59% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Earnings per Share (EPS) Deciphera Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

Earnings per Share measures the portion of a company's profit allocated to each outstanding share. It is a key metric for assessing a company's profitability on a per-share basis.

EPS = Net Income / Shares Outstanding

Access this data via the Eulerpool API

Income Statement — Deciphera Pharmaceuticals

All Key Metrics — Deciphera Pharmaceuticals